journal
MENU ▼
Read by QxMD icon Read
search

Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology

journal
https://www.readbyqxmd.com/read/27893337/inflammatory-cytokines-and-comorbidity-development-in-breast-cancer-survivors-versus-noncancer-controls-evidence-for-accelerated-aging
#1
Catherine M Alfano, Juan Peng, Rebecca R Andridge, Monica E Lindgren, Stephen P Povoski, Adele M Lipari, Doreen M Agnese, William B Farrar, Lisa D Yee, William E Carson, Janice K Kiecolt-Glaser
Purpose The sequelae of cancer treatment may increase systemic inflammation and create a phenotype at increased risk of functional decline and comorbidities, leading to premature mortality. Little is known about how this trajectory compares with natural aging among peers of the same age without cancer. This longitudinal study investigated proinflammatory cytokines and comorbidity development over time among breast cancer survivors and a noncancer control group. Methods Women (N = 315; 209 with breast cancer and 106 in the control group) were recruited at the time of their work-up for breast cancer; they completed the baseline questionnaire, interview, and blood draw (lipopolysaccharide-stimulated production of interleukin [IL] -6, tumor necrosis factor-α, and IL-1β)...
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27893336/lobectomy-or-sublobectomy-for-small-non-small-cell-lung-cancer-the-question-remains
#2
Joachim Widder, Caroline Van De Wauwer, Johannes A Langendijk
No abstract text is available yet for this article.
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27893335/debated-role-of-ovarian-protection-with-gonadotropin-releasing-hormone-agonists-during-chemotherapy-for-preservation-of-ovarian-function-and-fertility-in-women-with-cancer
#3
Matteo Lambertini, Tommaso Falcone, Joseph M Unger, Kelly-Anne Phillips, Lucia Del Mastro, Halle C F Moore
No abstract text is available yet for this article.
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27893334/can-segmentectomy-still-be-proposed-as-an-alternative-to-lobectomy-in-2016
#4
Berardino De Bari, André Durham, Jean Bourhis, Mahmut Ozsahin
No abstract text is available yet for this article.
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27893333/population-level-survival-for-patients-with-chronic-myeloid-leukemia-higher-survival-in-sweden-than-internationally
#5
Dianne Pulte, Lina Jansen
No abstract text is available yet for this article.
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27893332/outcome-of-men-with-relapse-after-adjuvant-carboplatin-for-clinical-stage-i-seminoma
#6
Stefanie Fischer, Torgrim Tandstad, Matthew Wheater, Emilio Porfiri, Aude Fléchon, Jorge Aparicio, Dirk Klingbiel, Breda Skrbinc, Umberto Basso, Jonathan Shamash, Anja Lorch, Klaus-Peter Dieckmann, Gabriella Cohn-Cedermark, Olof Ståhl, Caroline Chau, Edurne Arriola, Kalena Marti, Paul Hutton, Brigitte Laguerre, Pablo Maroto, Jörg Beyer, Silke Gillessen
Purpose Adjuvant carboplatin is one of three management strategies that may follow inguinal orchiectomy in clinical stage I seminoma. However, little is known about the outcome of patients who experience a relapse after such treatment. Patients and Methods Data from 185 patients who relapsed after adjuvant carboplatin between January 1987 and August 2013 at 31 centers/groups from 20 countries were collected and retrospectively analyzed. Primary outcomes were disease-free survival and overall survival. Secondary outcomes were time to, stage at, and treatment of relapse as well as rate of subsequent relapses...
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27893331/multidisciplinary-approach-to-novel-therapies-in-cardio-oncology-research-manticore-101-breast-a-randomized-trial-for-the-prevention-of-trastuzumab-associated-cardiotoxicity
#7
Edith Pituskin, John R Mackey, Sheri Koshman, Davinder Jassal, Marshall Pitz, Mark J Haykowsky, Joseph J Pagano, Kelvin Chow, Richard B Thompson, Larissa J Vos, Sunita Ghosh, Gavin Y Oudit, Justin A Ezekowitz, D Ian Paterson
Purpose The primary toxicity of trastuzumab therapy for human epidermal growth factor receptor 2-overexpressing (HER2-positive) breast cancer is dose-independent cardiac dysfunction. Angiotensin-converting enzyme inhibitors and β-blockers are recommended first-line agents for heart failure. We hypothesized that angiotensin-converting enzyme inhibitors and β-blockers could prevent trastuzumab-related cardiotoxicity. Patients and Methods In this double-blinded, placebo-controlled trial, patients with HER2-positive early breast cancer were randomly assigned to receive treatment with perindopril, bisoprolol, or placebo (1:1:1) for the duration of trastuzumab adjuvant therapy...
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27893330/reply-to-m-lambertini-et-al
#8
Isabelle Demeestere, Pauline Brice, Fedro A Peccatori, Alain Kentos, Jehan Dupuis, Pierre Zachee, Rene-Olivier Casasnovas, Eric Van Den Neste, Julie Dechene, Viviane De Maertelaer, Dominique Bron, Yvon Englert
No abstract text is available yet for this article.
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27893329/reaffirming-and-clarifying-the-american-society-of-clinical-oncology-s-policy-statement-on-the-critical-role-of-phase-i-trials-in-cancer-research-and-treatment
#9
Jeffrey S Weber, Laura A Levit, Peter C Adamson, Suanna S Bruinooge, Howard A Burris, Michael A Carducci, Adam P Dicker, Mithat Gönen, Stephen M Keefe, Michael A Postow, Michael A Thompson, David M Waterhouse, Susan L Weiner, Lynn M Schuchter
No abstract text is available yet for this article.
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27893328/what-s-in-a-name-steady-progress-in-staging-pancreatic-neuroendocrine-tumors
#10
Daniel M Halperin, James C Yao, Arvind Dasari
No abstract text is available yet for this article.
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27893327/radiation-therapy-for-glioblastoma-american-society-of-clinical-oncology-clinical-practice-guideline-endorsement-of-the-american-society-for-radiation-oncology-guideline
#11
Erik P Sulman, Nofisat Ismaila, Terri S Armstrong, Christina Tsien, Tracy T Batchelor, Tim Cloughesy, Evanthia Galanis, Mark Gilbert, Vinai Gondi, Mary Lovely, Minesh Mehta, Matthew P Mumber, Andrew Sloan, Susan M Chang
Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on radiation therapy for glioblastoma. Because of its relevance to the ASCO membership, ASCO reviewed the guideline and applied a set of procedures and policies used to critically examine guidelines developed by other organizations. Methods The ASTRO guideline on radiation therapy for glioblastoma was reviewed for developmental rigor by methodologists. An ASCO endorsement panel updated the literature search and reviewed the content and recommendations...
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27893326/randomized-prospective-biomarker-trial-of-ercc1-for-comparing-platinum-and-nonplatinum-therapy-in-advanced-non-small-cell-lung-cancer-ercc1-trial-et
#12
Siow Ming Lee, Mary Falzon, Fiona Blackhall, James Spicer, Marianne Nicolson, Abhro Chaudhuri, Gary Middleton, Samreen Ahmed, Jonathan Hicks, Barbara Crosse, Mark Napier, Julian M Singer, David Ferry, Conrad Lewanski, Martin Forster, Sally-Ann Rolls, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, Allan Hackshaw
Purpose Retrospective studies indicate that expression of excision repair cross complementing group 1 (ERCC1) protein is associated with platinum resistance and survival in non-small-cell lung cancer (NSCLC). We conducted the first randomized trial, to our knowledge, to evaluate ERCC1 prospectively and to assess the superiority of nonplatinum therapy over platinum doublet therapy for ERCC1-positive NSCLC as well as noninferiority for ERCC1-negative NSCLC. Patients and Methods This trial had a marker-by-treatment interaction phase III design, with ERCC1 (8F1 antibody) status as a randomization stratification factor...
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27893325/basket-trials-in-oncology-a-trade-off-between-complexity-and-efficiency
#13
Kristen M Cunanan, Mithat Gonen, Ronglai Shen, David M Hyman, Gregory J Riely, Colin B Begg, Alexia Iasonos
No abstract text is available yet for this article.
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27893324/reply-to-b-de-bari-et-al-and-j-widder-et-al
#14
Jianfei Shen, Chengyang Dai, Yaxing Shen, Rene Horsleben Petersen, Calvin S H Ng, Chia-Chuan Liu, Gaetano Rocco, Alessandro Brunelli, Chengchu Zhu, Chang Chen, Jianxing He
No abstract text is available yet for this article.
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27893323/ercc1-as-predictor-of-platinum-benefit-in-non-small-cell-lung-cancer
#15
Sophie Postel-Vinay, Jean-Charles Soria
No abstract text is available yet for this article.
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27893322/reply-to-m-lambertini-et-al
#16
Kutluk Oktay, Volkan Turan, Giuliano Bedoschi
No abstract text is available yet for this article.
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27893321/reply-to-d-pulte-et-al
#17
Hannah Bower, Magnus Björkholm, Paul W Dickman, Martin Höglund, Paul C Lambert, Therese M-L Andersson
No abstract text is available yet for this article.
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27870575/reply-to-d-a-palma
#18
Chi-Fu Jeffrey Yang, Derek Y Chan, Thomas A D'Amico, Mark F Berry, David H Harpole
No abstract text is available yet for this article.
November 21, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27870574/evaluation-of-bgj398-a-fibroblast-growth-factor-receptor-1-3-kinase-inhibitor-in-patients-with-advanced-solid-tumors-harboring-genetic-alterations-in-fibroblast-growth-factor-receptors-results-of-a-global-phase-i-dose-escalation-and-dose-expansion-study
#19
Lucia Nogova, Lecia V Sequist, Jose Manuel Perez Garcia, Fabrice Andre, Jean-Pierre Delord, Manuel Hidalgo, Jan H M Schellens, Philippe A Cassier, D Ross Camidge, Martin Schuler, Ulka Vaishampayan, Howard Burris, G Gary Tian, Mario Campone, Zev A Wainberg, Wan-Teck Lim, Patricia LoRusso, Geoffrey I Shapiro, Katie Parker, Xueying Chen, Somesh Choudhury, Francois Ringeisen, Diana Graus-Porta, Dale Porter, Randi Isaacs, Reinhard Buettner, Jürgen Wolf
Purpose This two-part, first-in-human study was initiated in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors (FGFRs) to determine the maximum tolerated dose (MTD), the recommended phase II dose (RP2D), and the schedule, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of oral BGJ398, a selective FGFR1-3 tyrosine kinase inhibitor. Patients and Methods Adult patients were treated with escalating dosages of BGJ398 5 to 150 mg once daily or 50 mg twice daily continuously in 28-day cycles...
November 21, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27870573/reply-to-c-g-drake
#20
Mark N Stein, Thomas L Jang
No abstract text is available yet for this article.
November 21, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
journal
journal
20146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"